Cousins Properties announced it will release its third quarter 2026 earnings after market close on October 29, 2026. The company will hold a conference call to discuss the results on October 30, 2026, at 10:00 a.m. Eastern Time, accessible via phone and webcast on their website. Financial details will be promptly available online, providing investors with insights into the company's performance in high-growth Sun Belt office markets. This event is important for shareholders and potential investors tracking Cousins' real estate investments and strategy.
Cousins Properties' upcoming third quarter 2026 earnings release and conference call provide context for real estate market activity. For readers following the real estate sector, here is Pluang's market snapshot as of Oct 02, 2026 03:22 WIB: Among 26 priced US real estate stocks, 11 rose and 15 fell. Innovative Industrial Properties Inc (IIPR) traded at USD 51.74 with a 1-day change of -1.86% and full buy-side Pluang order activity, contrasting with Apartment Investment and Management Co (AIV) at USD 2.02, which rose 1.77% with similar buy-side interest.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
